203 results
8-K
EX-99.1
DVAX
Dynavax Technologies Corporation
6 Aug 24
Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates
4:05pm
market opportunity by 2030. Dynavax also expects HEPLISAV-B to achieve a majority share of the total U.S. market by 2027, with share gains continuing post
8-K
EX-99.1
DVAX
Dynavax Technologies Corporation
8 May 24
Dynavax Reports First Quarter 2024 Financial Results
4:05pm
., and the vast majority remaining unvaccinated,” said Ryan Spencer, Chief Executive Officer of Dynavax.
“We’re also excited for several upcoming milestones from … a majority market share.
Clinical Pipeline
Dynavax is advancing a pipeline of differentiated product candidates that leverage its CpG 1018® adjuvant, which
8-K
EX-99.1
kgg5px8fzw3n735s 6o
22 Feb 24
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results
4:05pm
8-K
EX-99.1
9f05kjjlm04npphy16
8 Jan 24
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
9:05am
S-3ASR
EX-4.8
8jf14uuuci8w
3 Aug 23
Automatic shelf registration
5:26pm
S-3ASR
tm4zi gmcf
3 Aug 23
Automatic shelf registration
5:26pm
8-K
EX-99.1
7734skn1 nfrmmbp
3 Aug 23
Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
4:11pm
8-K
EX-99.1
bmr4f1qenxq6
2 May 23
Dynavax Reports First Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
c8doy
5 May 22
Dynavax Reports First Quarter 2022 Financial Results
4:04pm